A Model for In-vivo Delivered Dose Estimation for InhaledBacillus anthracisSpores in Humans with Interspecies Extrapolation

2011 ◽  
Vol 45 (13) ◽  
pp. 5828-5833 ◽  
Author(s):  
Mark H. Weir ◽  
Charles N. Haas
2019 ◽  
Vol 133 ◽  
pp. S36-S37
Author(s):  
E. Jørgensen ◽  
S. Rylander ◽  
S. Buus ◽  
L. Bentzen ◽  
S.B. Hokland ◽  
...  

2018 ◽  
Vol 115 (1) ◽  
pp. 90-101 ◽  
Author(s):  
Lourdes Cruz-Garcia ◽  
Grainne O’Brien ◽  
Ellen Donovan ◽  
Lone Gothard ◽  
Sue Boyle ◽  
...  

2004 ◽  
Vol 41 (sup4) ◽  
pp. 124-127
Author(s):  
Hyong Geun Yun ◽  
Soon Nyung Huh ◽  
Hyoung Koo Lee ◽  
Hong Gyun Woo ◽  
Kyo Chul Shin ◽  
...  

2014 ◽  
Vol 111 ◽  
pp. S224-S225
Author(s):  
G. Pastore ◽  
V. Reggioli ◽  
F. Casamassima ◽  
C. Menichelli ◽  
A. Fanelli

2010 ◽  
Vol 98 (2) ◽  
pp. 327-338 ◽  
Author(s):  
Benjamin B. Williams ◽  
Ruhong Dong ◽  
Maciej Kmiec ◽  
Greg Burke ◽  
Eugene Demidenko ◽  
...  

2014 ◽  
Vol 111 ◽  
pp. S93
Author(s):  
Y.G. Roussakis ◽  
H. Dehghani ◽  
S. Green ◽  
G.J. Webster

2018 ◽  
Vol 24 (3) ◽  
pp. 103-108
Author(s):  
Gowri Balan ◽  
Anu Radha Chandrasekaran ◽  
Ramasubramanian Velayudham ◽  
Gopiraj Annamalai ◽  
Mohan Ramachandran

Abstract Purpose: To estimate the midpoint dose delivered to cervical cancer patients treated by conventional technique using Electronic Portal Imaging Device (EPID). Materials and Methods: Clinac 2100 equipped with aS500 EPID was used in this study. A methodology was developed to generate a Gy/Calibration Unit (CU) look up table for the determination of midpoint dose of patients. 25 patients of cervical cancer were included in this study and the delivered dose to the midpoint of the patients was estimated using EPID. The deviation between the prescribed and the measured dose was calculated and analysed. Results: EPID showed a linear response with increase in Monitor unit and the Gy/CU look up table was validated for different field sizes and depth. 250 fields were measured for 25 patients, 10 measurements per patient, weekly once and for 5 weeks. The results show that out of 250 measurements, 98% of the measurements are within ±5% and 83.2% are within ±3% for with a standard deviation of 1.66%. Conclusion: The outcome of this study proves the efficacy of this methodology for the estimation of midpoint dose using EPID with minimal effort, time and without any inconvenience to the patients unlike other in-vivo dosimeters.


Sign in / Sign up

Export Citation Format

Share Document